Cardiac Rehabilitation in Heart Failure

Definition

Cardiac rehabilitation (CR) in HF is a physician-supervised, comprehensive, multidisciplinary intervention comprising individualized exercise training (ET), patient education, nutritional counseling, risk factor modification, and psychosocial assessment. It is distinct from exercise programs alone. CR is a Class I, Level of Evidence A recommendation in ACC/AHA HF guidelines for ambulatory, symptomatic (Stage C) patients with NYHA class II–III HF on GDMT.

Key Concepts

Underuse and Barriers

• Participation rates 10–30% worldwide despite Class 1A guideline status (sources/crp-hf-jacc-2021, rating: high)
• Key barriers: physician lack of awareness, inadequate referral, mandatory 6-week CMS wait, poor payer reimbursement, patient travel/cost/adherence challenges; women, minorities, and elderly are disproportionately under-referred (sources/crp-hf-jacc-2021, rating: high)
• Automatic EHR-based referral doubles enrollment (sources/crp-hf-jacc-2021, rating: high)
• Long-term adherence was <30% even in the highly supervised HF-ACTION trial

Pathophysiology of Exercise Intolerance in HF

• Multifactorial: inadequate cardiac output and high filling pressures → early anaerobic metabolism; skeletal muscle dysfunction (altered fiber composition, reduced oxidative capacity, impaired peripheral oxygen extraction); endothelial dysfunction; increased sympathetic activation and inflammatory cytokines (sources/crp-hf-jacc-2021, rating: high)
• ET reverses neurohormonal/inflammatory activation, ventricular remodeling, and improves endothelial function and skeletal muscle morphology (sources/crp-hf-jacc-2021, rating: high)
• Chronotropic incompetence is a key limiter in HFpEF specifically

Exercise Modalities

Aerobic/Moderate Continuous Training (MCT)

• Mainstay; suitable for all fitness levels especially <3 METs; safer in LVAD and early post-transplant patients (sources/crp-hf-jacc-2021, rating: high)
• Reverses LV remodeling in stable HF; improves peak VO2 and CV risk factors

Resistance Training

• Improves submaximal exercise capacity, muscle strength, and QOL (sources/crp-hf-jacc-2021, rating: high)
• Does not significantly change LVEF but improves skeletal muscle function and peripheral vascular responsiveness
• Complementary to aerobic exercise — not a substitute; especially important in sarcopenic, older, and female patients
• Elastic bands can be deployed at home for targeted muscle groups

High-Intensity Interval Training (HIIT)

• SMARTEX-HF (large multicenter RCT): HIIT not superior to MCT in LV remodeling or aerobic capacity in HFrEF (sources/crp-hf-jacc-2021, rating: high)
• Meta-analyses suggest greater exercise tolerance improvement and possibly higher peak VO2 with HIIT; no significant difference in safety events vs MCT
• HIIT requires judicious patient selection, more staff, and protocol standardization; may be perceived as HIIT by deconditioned patients even at MCT intensities

Inspiratory Muscle Training

• Widespread inspiratory muscle weakness in HF; beneficial in stable HF with respiratory muscle weakness (sources/crp-hf-jacc-2021, rating: high)
• Meta-analysis: improved 6-min walk distance, peak VO2, and minute ventilation vs sham/control
• Addition to aerobic training reduces dyspnea, increases exercise time, and improves QOL

Localized Muscle Training

• Improves exercise capacity via peripheral adaptations (muscle structure, oxygen transport/utilization) without requiring increased cardiac output
• Particularly useful in severely disabled patients with minimal reserve capacity (sources/crp-hf-jacc-2021, rating: high)

Exercise Prescription (FITT Framework)

• Frequency, Intensity, Time, Type
• Target: aerobic ET at 50–80% of peak capacity, up to 45 min, most days of the week (sources/crp-hf-jacc-2021, rating: high)
• HF-ACTION protocol:
  • 36 supervised sessions (3×/week goal); initial 6 sessions at 60% HRR; remaining sessions 60–70% HRR
  • Home maintenance phase: 40 min, 5×/week; 10-min warm-up/cool-down
  • Starting point for advanced symptoms: 50% HRR, 15–30 min with rest periods
  • AF or frequent ectopy: Borg scale 12–14 instead of heart rate reserve
  • Beta-blocked patients unable to reach target HR: Borg 12–14
  • Exercise-induced ischemia: HR 10 bpm below ischemic threshold
• Lifestyle exercise (for those not in formal CR): start <60% HRR or resting HR +30 bpm; increase duration every 2–4 weeks to 45 min total; then titrate intensity
• Monitoring: symptoms, NYHA class, QOL, peak VO2 (CPET), 6-min walk distance

Evidence in HFrEF

• ~15–17% improvement in peak VO2; significant improvements in QOL (including physical and social subscales) (sources/crp-hf-jacc-2021, rating: high)
• HF hospitalization reduced in meta-analyses; mortality reduction suggested with longer follow-up and among adherent patients
• LVEF improvements modest/inconsistent — LVEF should not be the primary target or marker of benefit; most patients improve functionally without LVEF change (sources/crp-hf-jacc-2021, rating: high)

Evidence in HFpEF

• Consistent evidence for improved exercise capacity and health-related QOL (sources/crp-hf-jacc-2021, rating: high)
• Inconsistent findings on LV diastolic function, compliance, and arterial stiffness across trials
• CMS currently provides no coverage for CR in HFpEF despite evolving evidence

Evidence After Acute HF Hospitalization

• EJECTION-HF: supervised ET safe and feasible post-acute-HF hospitalization; did not reduce death or readmission
• REHAB-HF (ongoing): physical function intervention (balance, mobility, strength, endurance) in older hospitalized HF patients

Evidence in Advanced HF / LVAD

• Rehab-VAD: moderate-intensity aerobic training safe in continuous-flow LVAD; improved health status, treadmill time, leg strength; no significant peak VO2 improvement (sources/crp-hf-jacc-2021, rating: high)
• MCT preferred over HIIT in LVAD due to autonomic/circulatory hysteresis

CMS Coverage Criteria (USA, 2021)

• LVEF ≤35%, NYHA class II–IV, despite ≥6 weeks of optimal HF therapy; up to 36 sessions
• Stability = no major CV hospitalization/procedure in preceding 6 weeks or planned within 6 months
• No coverage for HFpEF (unchanged at time of publication)

Future Directions

• Home-based, telemedicine, and hybrid CR models rapidly expanding (COVID-19 accelerated this)
• Remove mandatory 6-week CMS wait period; allow concurrent GDMT optimization and CR
• Wearable and implantable activity monitoring to reduce recidivism
• Yoga and tai chi as complementary modalities to traditional ET (sources/CAM-in-Heart-Failure)

Contradictions / Open Questions

• HIIT vs MCT: small studies favored HIIT but SMARTEX-HF large RCT showed no superiority; optimal patient selection for HIIT remains undefined (sources/crp-hf-jacc-2021, rating: high)
• LVEF as outcome marker: most trials showed only modest or non-significant LVEF improvements from ET; functional benefit occurs independently of LVEF change — LVEF should not be the primary endpoint for CR benefit (sources/crp-hf-jacc-2021, rating: high)
• HFpEF ET effects on LV function: inconsistent across studies; exercise capacity and QOL reliably improve, but cardiac structural/functional improvement is variable (sources/crp-hf-jacc-2021, rating: high)
• Post-acute HF hospitalization: EJECTION-HF showed feasibility but not clinical outcome benefit; evidence base is insufficient to guide coverage (sources/crp-hf-jacc-2021, rating: high)

Connections

• Related to concepts/Cardiopulmonary-Exercise-Testing — CPET used for baseline exercise evaluation and prescription in CR
• Related to concepts/CAM-in-Heart-Failure — yoga and tai chi as complementary CR modalities
• Related to concepts/HF-COPD-Comorbidity — COPD coexistence affects ET tolerance and prescription
• Related to concepts/Iron-Deficiency-in-HF — nutritional assessment is a CR component
• Related to concepts/Cardiac-Resynchronization-Therapy — CRT and CR may have synergistic effects in HFrEF

Sources

• sources/crp-hf-jacc-2021